Emx2 as a novel tool to suppress glioblastoma
Metrics: PDF 1176 views | HTML 1460 views | ?
Carmen Falcone1, Antonio Daga2, Giampiero Leanza3, Antonello Mallamaci1
1Department of Neuroscience, SISSA, 34136 Trieste, Italy
2DIPOE, IRCCS AOU San Martino IST, 16132 Genoa, Italy
3Department of Life Sciences, University of Trieste, 34127 Trieste, Italy
Antonello Mallamaci, email: email@example.com
Keywords: Emx2, glioblastoma, gene therapy, EGFR, SOX2
Received: February 28, 2016 Accepted: April 26, 2016 Published: May 13, 2016
Glioblastoma is a devastating CNS tumour for which no cure is presently available. We wondered if manipulation of Emx2, which normally antagonizes cortico-cerebral astrogenesis by inhibiting proliferation of astrocyte progenitors, may be employed to counteract it. We found that Emx2 overexpression induced the collapse of seven out of seven in vitro tested glioblastoma cell lines. Moreover, it suppressed four out of four of these lines in vivo. As proven by dedicated rescue assays, the antioncogenic activity of Emx2 originated from its impact on at least six metabolic nodes, which accounts for the robustness of its effect. Finally, in two out of two tested lines, the tumor culture collapse was also achieved when Emx2 was driven by a neural stem cell-specific promoter, likely active within tumor-initiating cells. All that points to Emx2 as a novel, promising tool for therapy of glioblastoma and prevention of its recurrencies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.